Business Wire

Ant Group Launches AI-Powered Mobile App Zhixiaobao at 2024 INCLUSION·Conference on the Bund

5.9.2024 10:55:00 CEST | Business Wire | Press release

Share

Other AI-powered products were also introduced to make AI more accessible for industries and consumers

At the 2024 INCLUSION · Conference on the Bund in Shanghai, Ant Group launched the Zhixiaobao mobile app, an AI life assistant that better connects users with all kinds of life services on the company’s digital life platform Alipay. The app is available for download from iOS and Android app stores.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904932587/en/

Ant Group unveiled AI life assistant app – Zhixiaobao, at the 2024 INCLUSION · Conference on the Bund. (Graphic: Business Wire)

As an AI-native application powered by Ant Group’s BaiLing foundation model, Zhixiaobao is designed to make everyday tasks easier through user-friendly interactions. Through typing or voice chat in Zhixiaobao, users can order meals, hail taxis, book tickets, and discover local dining and entertainment options, accessing third-party services in Alipay more easily.

The app also provides a number of built-in AI agents, each with specific domain knowledge that makes them an expert in their own fields. For example, the “English Language Tutor” agent can help users make a learning plan and provide tips for learning the language. The “Fitness Pro” agent can help users design workout routines and come up with personalized training advice.

"The evolution of AI extends beyond mere technological progress, it’s about applying these advancements to practical, user-focused solutions. Alipay is committed to harnessing AI’s potential to improve the user experience, ensuring that AI assistants like Zhixiaobao become valuable tools in everyday life for all," said Cyril Han, President of Ant Group.

To use Zhixiaobao’s services, users can either download the dedicated mobile app, or simply pull down the home page of the Alipay app.

In addition to Zhixiaobao, Ant Group also introduced other AI-powered products and solutions at the INCLUSION Conference.

  • An AI Agent Development Platform: A comprehensive, one-stop platform enabling merchants to create customized AI service agents which can be deployed in just one minute, without the need for coding. These agents can be effortlessly integrated into the Alipay mini-programs operated by merchants, the Alipay app, and the Zhixiaobao app.
  • AI Healthcare Manager: An AI-powered platform that connects users to over 30 health services, including doctor recommendations, medical test result interpretation, in-hospital navigation, and personalized medical advice. The AI Healthcare Manager is supported by over 20 service providers, including Renji Hospital in Shanghai.
  • Ant Bridge: An open platform that leverages advanced technologies including AI models and financial intelligence, to assist insurance companies in providing personalized responses to customer inquiries in real-time. The platform is designed to support insurers to enhance their service quality while boosting operational efficiency.

Ant Group unveiled its BaiLing foundation model in 2023. Over the past two years, Ant Group has accelerated the application of AI technologies in the Alipay app, serving hundreds of millions of users across various life service use cases, including travel, healthcare, and financial management.

About Ant Group

Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.

For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904932587/en/

Contacts

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye